Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2001-11-28
2008-10-14
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
07435755
ABSTRACT:
CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.
REFERENCES:
patent: 4395423 (1983-07-01), Neumann
patent: 5064823 (1991-11-01), Lee et al.
patent: 5603958 (1997-02-01), Morein et al.
patent: 6326507 (2001-12-01), Gribble et al.
patent: 6485756 (2002-11-01), Aust et al.
patent: 2002/0042535 (2002-04-01), Gribble et al.
patent: WO 99/65478 (1999-12-01), None
Elstner et al. Ligands for peroxisome proliferator-activated receptor [gamma] and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA, 1998, v. 95, pp. 8806-8811.
Al-alami et al., Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U937 CD34 negative human leukaemia cells. Leukemia Research, 1998, v. 22, pp. 939-945.
Lieu et al. Dual cytotoxic mechanisms of submicromolar taxol on human leukemia HL-60 cells. Biochemical Pharmacology, 1997, v. 53, pp. 1587-1596.
Kurbacher et al. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Letters, 1996, v. 103, pp. 183-189.
Gura et al. Systems for identifying new drugs are often faulty. Science, 1997, 278:1041-1042.
Johnson et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British J. of Cancer, 2001, 84(10):1424-1431.
Agarwal and Mehta, “Possible involvement of Bcl-2 pathway in retinoid X receptor alpha-induced apoptosis of HL-60 cells,”Biochem Biophys Res Common, 230(2):251-253, 1997.
Andreeff et al., “Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and cationic acid,”Leukemia, 13:1881-1892, 1999.
Andreeff, “Acute myeloid leukemia,”In: Cancer Treatment, Haskell (Ed.), W. B. Saunders, 911-922, 1995.
Beran et al., “Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia,”J. Clinical Oncology, 17(9):2819-2830, 1999.
Carter et al., “Expression of survivin, a member of the inhibitor of apoptosis (IAP) family of caspase inhibitors is expressed in AML and regulated by cytokines and ATRA,”Blood, 94(Suppl 1):479a, Abstract # 2142, 1999.
Castaigne et al., “All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia,”Blood, 76(9):1704-1709, 1990.
Drach et al., “Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid,”Cancer Research, 53:2100-2104, 1993.
Engel et al., “Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells,”Leukemia, 13:568-577, 1999.
Estey et al., “Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia,”Blood, 94:2230-2235, 1999.
Estey et al., “Randomized phase II study of fludarabine+cytosine arabinoside+idarubicin+all-trans retinoic acid+granulocyte-colony stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrom,”Blood, 93(8):2478-2484, 1998.
Kim et al., “Capasase-3 activation is involved in apoptosis induced by a synthetic triterpenoid in Non-small cell lung cancer (NSCLC) cells,”Proc. Amer, Assoc. Cancer Res., 41:770, Abstract #4894, 2000.
Konopleva and Andreeff, “Regulatory pathways in programmed cell death,”Cancer Mol Biol., 6:1229-1260, 1999.
Konopleva et al., “Apoptosis: molecules and mechanisms,”Adv Exp Med Biol, 457:217-236, 1998.
Konopleva et al., “Engraftment potential of AML progenitors into NOD/scid mice is dependent on baseline CXCR4 expression,”Blood, 94(Suppl 1):166b, Abstract #3916, 1999.
Konopleva et al., “Novel synthetic triterpenoid, CDDO, and its methyl ester: Potent antiproliferative, proapoptotic and differentiating agents in AML,”Blood, 94(Suppl 1):479a, Abstraact #2140, 1999.
Konopleva et al., “Novel triterpenoid CDD0-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia,”Blood, 99(1):326-335, 2002.
Konopleva et al., “PPARγ nuclear receptor as a novel therapeutic target in AML,”Blood, 96(11):460a, Abstract #1982, 2000.
Kornblau et al., “Phase I study of mitoxantrone plus etoposide with mutidrug blockage by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia,”J. Clin. Oncol., 15(5):1796-1802, 1997.
Mehta et al., “Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells,”Cell, Growth Differ, 7(2): 179-186, 1996.
Sporn et al., “Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs),”Trends in Molecular Medicine, 7(9):395-400, 2001.
Suh et al., “A novel synthetic oleanane triterpenoid, 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity,”Cancer Res., 59(2):336-341, 1999.
Tamm et al., “Expression and prognostic significance of IAP-family genes in human cancers and leukemias,”Blood, 94 (Suppl. 1):69a, Abstract # 298, 1999.
Walczak et al., “Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo”,Nature Medicine,5(2):157-163, 1999.
Wang et al., “A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma,”Mol.Endocrinol., 14(10): 1550-1556, 2000.
Warrell et al., “Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid),”N. Engl. J. Med., 324(20):1385-1393, 1991.
Xie et al., “Differential expression patterns in human myeloblastic leukemia HL-60 and multidrug resistant HL-60/Dox cells analyzed by human cDNA expression array,”Blood, 92 (Suppl 1):387a, Abstract #1600. 1998.
Ito et al., “The novel triterpenoid 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism,”Cell Growth&Differentiation, 11(5):261-267, 2000.
Konopleva et al., “Novel synthetic triterpenoid CDDO-Me: potent antiproliferative, proapoptotic and differentiating agent in AML,”Blood, 96(11), Part 1: 121A, abstract # 522, 2000.
Ruvolo et al., “The novel triterpenoid methyl-CDDO inhibits Bc12 phosphorylation and potently kolls U937 cells,”Blood, 94(10), Suppl. 1, Part 1: 280A, abstract #1251, 1999.
Suh et al., “A novel synthetic oleanane triterpenoid, 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid (CDDO), induces cell differentiaion in human myeloid leukemias,”Proceedings of the American Association for Cancer Research Annual Meeting, 40:300, abstract # 1988, 1999.
Wang et al., “A novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) induces adipocyte differentiation in 3T3-L1 cells,”Proceedings of the American Association for Cancer Research Annual Meeting, 40:300, abstract # 1989, 1999.
Ambs et al., “p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells,”Nat. Med., 4(12):1371-1376, 1998.
Andreeff et al., “PPARgamma nuclear receptor as a novel molecular target in leukemias,”2002 Keystone Symposia, Abstract No. 501, 2002.
Bliard et al., “Glycosylation o
Andreeff Michael
Konopleva Marina
Sporn Michael B.
Anderson James D
Board of Regents , The University of Texas System
Fulbright & Jaworski
Marschel Ardin
The Trustees of Dartmouth College
LandOfFree
CDDO-compounds and combination therapies thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CDDO-compounds and combination therapies thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CDDO-compounds and combination therapies thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3999699